Record overview
Status and phase
Status: NOT_YET_RECRUITING
Phase: PHASE2
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Condition: Triple Negative Breast Cancer (TNBC), PD-L1 Positive
NCT07153965
Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.